The gram-negative bacterium Helicobacter pylori is known as a persistent colonizer of the human stomach, and probably less known is that it is also involved in extraintestinal diseases. Public awareness of its contribution in the development of gastric cancer is less than 15 years old. The efficacy of the current therapies based on antibiotics against H. pylori has been limited by difficulties such as antibiotic resistance and recurrence. As a consequence, the development of promising vaccines was prompted as the best preventive measure. Unfortunately, so far vaccines failed the transition from animal models to human trials. This keynote presentation is to provide a bird's eye view of H. pylori-related gastric diseases, including gastric cancer, with a synthesis of the molecular mechanisms involved, and an exhaustive presentation and discussion of the current therapeutic guidelines and future strategies for prevention or therapy.

Vogiatzi, P., Cassone, M., Luzzi, I., Lucchetti, C., OTVOS L., J.r., & Giordano, A. (2007). Helicobacter pylori as a class I carcinogen: Physiopathology and management strategies. JOURNAL OF CELLULAR BIOCHEMISTRY, 102(2), 264-273.

Helicobacter pylori as a class I carcinogen: Physiopathology and management strategies.

LUCCHETTI, CHIARA;GIORDANO, ANTONIO
2007

Abstract

The gram-negative bacterium Helicobacter pylori is known as a persistent colonizer of the human stomach, and probably less known is that it is also involved in extraintestinal diseases. Public awareness of its contribution in the development of gastric cancer is less than 15 years old. The efficacy of the current therapies based on antibiotics against H. pylori has been limited by difficulties such as antibiotic resistance and recurrence. As a consequence, the development of promising vaccines was prompted as the best preventive measure. Unfortunately, so far vaccines failed the transition from animal models to human trials. This keynote presentation is to provide a bird's eye view of H. pylori-related gastric diseases, including gastric cancer, with a synthesis of the molecular mechanisms involved, and an exhaustive presentation and discussion of the current therapeutic guidelines and future strategies for prevention or therapy.
Vogiatzi, P., Cassone, M., Luzzi, I., Lucchetti, C., OTVOS L., J.r., & Giordano, A. (2007). Helicobacter pylori as a class I carcinogen: Physiopathology and management strategies. JOURNAL OF CELLULAR BIOCHEMISTRY, 102(2), 264-273.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11365/4045
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo